ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been given an average rating of "Buy" by the eight analysts that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.00.

A number of brokerages have recently issued reports on PRQR. Evercore ISI reissued an "outperform" rating on shares of ProQR Therapeutics in a research report on Friday, July 11th. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. JMP Securities reissued a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. Finally, Oppenheimer cut their price objective on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in shares of ProQR Therapeutics by 11.8% in the 4th quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company's stock valued at $217,000 after acquiring an additional 8,621 shares during the period. Jane Street Group LLC purchased a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $30,000. Squarepoint Ops LLC raised its stake in shares of ProQR Therapeutics by 16.3% in the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock valued at $220,000 after acquiring an additional 11,623 shares during the period. Invesco Ltd. purchased a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $32,000. Finally, OneDigital Investment Advisors LLC increased its stake in ProQR Therapeutics by 45.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 12,500 shares during the period. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Stock Down 1.3%

Shares of PRQR stock traded down $0.03 during trading hours on Friday, hitting $2.23. 146,015 shares of the company's stock traded hands, compared to its average volume of 274,103. The stock's fifty day simple moving average is $1.99 and its two-hundred day simple moving average is $1.90. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The stock has a market cap of $234.62 million, a price-to-earnings ratio of -6.37 and a beta of 0.36.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative net margin of 157.04% and a negative return on equity of 53.49%. On average, equities analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).